Completed PHASE4 INTERVENTIONAL NCT00297973

Cardiovascular Risk Assessment in Patients Treated With Caduet (RIGHT)

Cardiovascular Risk Assessment In Patients With Hypertension And At Least Three Other Risk Factors, Treated With Caduet Compared To Usual Care: The Right Study

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions Hypertension

Interventions Blood pressure measurements Blood samples

Updated 7 times since 2017 Last updated: Jan 26, 2021 Started: Feb 28, 2006 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Hypertension, this trial is completed. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 7 data snapshots since 2006. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Feb 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Feb 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbeville, France , Aire-sur-la-Lys, France , Aix-les-Bains, France , Alençon, France , Allaire, France , Amboise, France , Amiens, France , Andrézieux-Bouthéon, France , Angers, France , Annecy, France and 332 more locations